Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2021-03-31 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Antalet aktier och röster i Ascelia Pharma AB
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Ascelia Pharma announcing a change in the total number of shares and votes due to the exercise of warrants. This type of disclosure is a standard regulatory requirement for listed companies to report changes in share capital. According to the provided categories, 'SHA' (Share Issue/Capital Change) is the most accurate classification for announcements regarding new share issues or capital structure changes.
2021-03-31 Swedish
Number of shares and votes in Ascelia Pharma AB
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a change in the total number of shares and votes in Ascelia Pharma AB due to the exercise of warrants. This type of disclosure regarding changes in share capital and voting rights is classified as a 'Share Issue/Capital Change' announcement.
2021-03-31 English
Audit Report / Information 2020
Audit Report / Information Classification · 98% confidence The document is titled "ÅRSREDOVISNING 2020" (Annual Report 2020) in Swedish. It contains a detailed table of contents listing sections typical of an annual report, such as 'VD HAR ORDET' (CEO's Statement), 'FÖRVALTNINGSBERÄTTELSE' (Directors' Report), financial statements ('Koncernens resultaträkning', 'Koncernens balansräkning'), and the 'REVISIONSBERÄTTELSE' (Auditor's Report). Furthermore, it includes a 'Financial Calendar' detailing future earnings releases and the Annual General Meeting (Årsstämma). The length (309,637 characters) confirms it is a comprehensive document, not just an announcement. Although the definition for '10-K' specifies the US SEC filing, in a global context, a comprehensive, audited Annual Report is best classified as 'AR' (Audit Report / Information) or potentially '10-K' if the context strongly implied US GAAP/SEC, but given the Swedish language and structure, 'AR' (Audit Report / Information) is the most appropriate fit among the provided options for a full annual report containing audited financials, especially since '10-K' is strictly defined as the official yearly report covering company activity and full financial performance, which this document clearly is, despite the language difference. Given the comprehensive nature covering the entire year and including the auditor's report, it aligns best with the spirit of a full annual report, which maps closely to the 10-K structure, but since 'AR' covers standalone audit reports and '10-K' covers the full annual report, and this document is the full annual report, '10-K' is the closest match for a full annual report, even if it's not the SEC form itself. However, looking closely at the definitions, '10-K' is specifically for the SEC filing. 'AR' is for standalone audit reports. Since this document *contains* the audit report and is the full annual report, and '10-K' is too specific to the SEC form, 'AR' is often used as the general category for comprehensive annual financial reporting documents when '10-K' is reserved for the specific SEC filing. Given the presence of the full financial statements and the auditor's report, it is a comprehensive annual report. I will select 'AR' as the best fit for a comprehensive annual report containing the audit, as '10-K' is too restrictive to the SEC form name. FY 2020
2021-03-30 Swedish
Annual Report 2020
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2020' and contains comprehensive sections including CEO comments, strategic direction, detailed financial statements (Income Statement, Balance Sheet, Cash Flow), auditor's report, and notes to the financial statements. It covers the full fiscal year 2020 for Ascelia Pharma. This matches the definition of an Annual Report (10-K). FY 2020
2021-03-30 English
Kallelse till extra bolagsstämma i Ascelia Pharma AB
Proxy Solicitation & Information Statement Classification · 98% confidence The document is titled "Kallelse till extra bolagsstämma i Ascelia Pharma AB" (Notice of Extraordinary General Meeting in Ascelia Pharma AB). It details the procedures for shareholders to participate via advance voting (poströstning) due to COVID-19 restrictions, outlines the proposed agenda (including a resolution on a directed new share issue), and specifies voting rights and deadlines. This content directly relates to calling a shareholder meeting and soliciting votes/information for it, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). Although it is a notice for an EGM, the core function described is soliciting shareholder participation and providing necessary information for voting decisions, making PSI the most appropriate fit over AGM-R (which is for presentations *during* the meeting) or DEF 14A (which is specifically for remuneration).
2021-03-17 Swedish
Notice of extraordinary general meeting in Ascelia Pharma
AGM Information Classification · 99% confidence The document is explicitly titled 'NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB' and details the procedures for shareholders to participate via advance voting (postal vote) on a specific date (Tuesday 13 April 2021). It outlines the agenda, proposed resolutions (including a directed issue of shares), and shareholder rights regarding information. This content directly relates to the formal proceedings and materials associated with a shareholder meeting, fitting the definition of 'AGM Information' (AGM-R), even though it is an Extraordinary General Meeting (EGM) notice, which falls under the general scope of AGM materials.
2021-03-17 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.